Search research articles
Contact Us
Filters
Showing results (21-30 of 70) with videos related to
Page
of 7
Sort By:
JCO Precision Oncology
|
November 9, 2020
Tumor Genomic Profiling Practices and Perceptions: A Survey of Physicians Participating in the NCI-MATCH Trial
Alice Chen, Keith Flaherty, Peter J O'Dwyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 2, 2013
Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth
Zhenyu Ji, Raj Kumar, Michael Taylor, et al.
The Oncologist
|
November 22, 2017
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results
Eileen M O'Reilly, James Roach, Paul Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 19, 2007
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer
Ronald M Bukowski, Fairooz F Kabbinavar, Robert A Figlin, et al.
Cancer Immunology, Immunotherapy : CII
|
March 14, 2019
Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition
Vylyny Chat, Robert Ferguson, Danny Simpson, et al.
Cancer Discovery
|
November 23, 2012
Elucidating distinct roles for NF1 in melanomagenesis
Ophélia Maertens, Bryan Johnson, Pablo Hollstein, et al.
JCO Oncology Advances
|
June 23, 2025
Impact of the COVID-19 Pandemic Mitigation Strategies on Cancer Treatment Trials: A Meta-Analysis of Industry and National Cancer Institute Studies
Joseph M Unger, Hillary S Andrews, Laura A Levit, et al.
Nature Medicine
|
October 19, 2018
Publisher Correction: Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
Noam Auslander, Gao Zhang, Joo Sang Lee, et al.
Nature Medicine
|
August 22, 2018
Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
Noam Auslander, Gao Zhang, Joo Sang Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 1, 2019
Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma
Wenxin Xu, Maneka Puligandla, Judith Manola, et al.
Page
of 7
Search research articles
Search
Showing results (21-30 of 70) with videos related to
Sort By:
Page
of 7
JCO Precision Oncology
|
November 9, 2020
Tumor Genomic Profiling Practices and Perceptions: A Survey of Physicians Participating in the NCI-MATCH Trial
Alice Chen, Keith Flaherty, Peter J O'Dwyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 2, 2013
Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth
Zhenyu Ji, Raj Kumar, Michael Taylor, et al.
The Oncologist
|
November 22, 2017
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results
Eileen M O'Reilly, James Roach, Paul Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 19, 2007
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer
Ronald M Bukowski, Fairooz F Kabbinavar, Robert A Figlin, et al.
Cancer Immunology, Immunotherapy : CII
|
March 14, 2019
Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition
Vylyny Chat, Robert Ferguson, Danny Simpson, et al.
Cancer Discovery
|
November 23, 2012
Elucidating distinct roles for NF1 in melanomagenesis
Ophélia Maertens, Bryan Johnson, Pablo Hollstein, et al.
JCO Oncology Advances
|
June 23, 2025
Impact of the COVID-19 Pandemic Mitigation Strategies on Cancer Treatment Trials: A Meta-Analysis of Industry and National Cancer Institute Studies
Joseph M Unger, Hillary S Andrews, Laura A Levit, et al.
Nature Medicine
|
October 19, 2018
Publisher Correction: Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
Noam Auslander, Gao Zhang, Joo Sang Lee, et al.
Nature Medicine
|
August 22, 2018
Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
Noam Auslander, Gao Zhang, Joo Sang Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 1, 2019
Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma
Wenxin Xu, Maneka Puligandla, Judith Manola, et al.
Page
of 7